BRAF and lung carcinoma: In melanoma, colorectal, and lung cancer, BRAF p.V600E is a well-known druggable (anti-EGFR therapy) hotspot affecting the kinase domain of the protein, recently classified as a class I mutant, with the strongest kinase activity, constitutive MAPK cascade, and RAS-independent [67,68].